102 Publications (Page 1 of 5)
2021
Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidenceNguyen, R.H.⋅Nguyen, Ryan H⋅Nguyen, Ryan H⋅Vater, L.B.⋅Vater, Laura B⋅Vater, Laura B⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, L.R.⋅Durm, Gregory A⋅Durm, Gregory A⋅Durm, G.A.⋅Rupp, K.⋅Rupp, Katelin⋅Rupp, Katelin⋅Wright, Keylee⋅Wright, Keylee⋅Wright, K.⋅Spitznagle, Miranda H⋅Spitznagle, M.H.⋅Spitznagle, Miranda H⋅Brandy, Paul⋅Brandy, Paul⋅Paul, B.⋅Jalal, S.I.⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, L.⋅Hudmon, Karen S⋅Hudmon, K.S.⋅Hudmon, Karen S⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, N.H.⋅Loehrer, Patrick J⋅Loehrer, P.J.⋅Loehrer, Patrick J⋅Ceppa, D.P.⋅Ceppa, DuyKhanh P and Ceppa, DuyKhanh PPLoS One, vol. 16, (no. 4), Apr 2021.
| Journal Article
2020
An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit FunctionRamchandani, Neal K⋅Ramchandani, Neal K⋅Kesler, Kenneth A⋅Kesler, Kenneth A⋅Rogers, Jonathon D⋅Rogers, Jonathon D⋅Valsangkar, Nakul⋅Valsangkar, Nakul⋅Stokes, Samatha M⋅Stokes, Samatha M⋅Jalal, Shadia I and Jalal, Shadia IJournal of visualized experiments : JoVE, (no. 158), 2020-Apr-17.
| Journal Article
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179Durm, Greg A⋅Durm, Greg A⋅Durm, Greg A⋅Durm, Greg A⋅Durm, Greg A⋅Jabbour, Salma K⋅Jabbour, Salma K⋅Jabbour, Salma K⋅Jabbour, Salma K⋅Jabbour, Salma K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Liu, Ziyue⋅Liu, Ziyue⋅Liu, Ziyue⋅Liu, Ziyue⋅Liu, Ziyue⋅Sadiq, Ahad A⋅Sadiq, Ahad A⋅Sadiq, Ahad A⋅Sadiq, Ahad A⋅Sadiq, Ahad A⋅Zon, Robin T⋅Zon, Robin T⋅Zon, Robin T⋅Zon, Robin T⋅Zon, Robin T⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Williamson, Michael J⋅Williamson, Michael J⋅Williamson, Michael J⋅Williamson, Michael J⋅Williamson, Michael J⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Langdon, Robert M⋅Langdon, Robert M⋅Langdon, Robert M⋅Langdon, Robert M⋅Langdon, Robert M⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Adesunloye, Bamidele A⋅Adesunloye, Bamidele A⋅Adesunloye, Bamidele A⋅Adesunloye, Bamidele A⋅Adesunloye, Bamidele A⋅Harb, Wael A⋅Harb, Wael A⋅Harb, Wael A⋅Harb, Wael A⋅Harb, Wael A⋅Walling, Radhika V⋅Walling, Radhika V⋅Walling, Radhika V⋅Walling, Radhika V⋅Walling, Radhika V⋅Titzer, Michael L⋅Titzer, Michael L⋅Titzer, Michael L⋅Titzer, Michael L⋅Titzer, Michael L⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H and Hanna, Nasser HCancer, vol. 126, (no. 19), pp. 4353-4361, Oct 2020.
| Journal Article
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma: A Big Ten Cancer Research Consortium studyMamdani, Hirva⋅Mamdani, Hirva⋅Mehta, Rutika⋅Mehta, Rutika⋅Fountzilas, Christos⋅Fountzilas, Christos⋅Radovich, Milan⋅Radovich, Milan⋅Perkins, Susan⋅Perkins, Susan⋅Jalal, Shadia Ibrahim and Jalal, Shadia IbrahimJournal of Clinical Oncology, vol. 38, (no. 4_suppl), pp. TPS472, 2020-02-01.
| Journal Article
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesChung, Hyun Cheol⋅Chung, Hyun Cheol⋅Piha-Paul, Sarina A.⋅Piha-Paul, Sarina A⋅Lopez-Martin, Jose⋅Lopez-Martin, Jose⋅Schellens, Jan H.M⋅Schellens, Jan H.M.⋅Kao, Steven⋅Kao, Steven⋅Miller, Wilson H⋅Miller, Wilson H.⋅Delord, Jean-Pierre⋅Delord, Jean-Pierre⋅Gao, Bo⋅Gao, Bo⋅Planchard, David⋅Planchard, David⋅Gottfried, Maya⋅Gottfried, Maya⋅Zer, Alona⋅Zer, Alona⋅Jalal, Shadia I.⋅Jalal, Shadia I⋅Penel, Nicolas⋅Penel, Nicolas⋅Mehnert, Janice M.⋅Mehnert, Janice M⋅Matos, Ignacio⋅Matos, Ignacio⋅Bennouna, Jaafar⋅Bennouna, Jaafar⋅Kim, Dong-Wan⋅Kim, Dong-Wan⋅Xu, Lei⋅Xu, Lei⋅Krishnan, Suba⋅Krishnan, Suba⋅Norwood, Kevin⋅Norwood, Kevin⋅Ott, Patrick A. and Ott, Patrick AJournal of Thoracic Oncology, vol. 15, (no. 4), pp. 627, April 2020.
| Journal Article
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.Voss, Martin H⋅Voss, MH⋅Gordon, MS⋅Gordon, Michael S⋅Mita, M⋅Mita, Monica⋅Rini, B⋅Rini, Brian⋅Makker, Vicky⋅Makker, V⋅Macarulla, Teresa⋅Macarulla, T⋅Smith, Dc⋅Smith, David C⋅Cervantes, A⋅Cervantes, Andrés⋅Puzanov, I⋅Puzanov, Igor⋅Pili, Roberto⋅Pili, R⋅Wang, Ding⋅Wang, D⋅Jalal, S⋅Jalal, Shadia⋅Pant, Shubham⋅Pant, S⋅Patel, Manish R⋅Patel, MR⋅Neuwirth, Rachel L⋅Neuwirth, RL⋅Enke, Aaron⋅Enke, A⋅Shou, Yaping⋅Shou, Y⋅Sedarati, Farhad⋅Sedarati, F⋅Faller, Douglas V⋅Faller, DV⋅Burris, HA and Burris, Howard ABritish journal of cancer, September 11, 2020.
| Journal Article
Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149Uboha, Nataliya Volodymyrivna⋅Uboha, Nataliya Volodymyrivna⋅Uboha, Nataliya Volodymyrivna⋅Eickhoff, Jens C.⋅Eickhoff, Jens C⋅Eickhoff, Jens C.⋅Chandrasekharan, Chandrikha⋅Chandrasekharan, Chandrikha⋅Chandrasekharan, Chandrikha⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Benson, Al Bowen⋅Benson, Al Bowen⋅Benson, Al Bowen⋅Deming, Dustin A.⋅Deming, Dustin A⋅Deming, Dustin A.⋅Lindemann, Stephen⋅Lindemann, Stephen⋅Lindemann, Stephen⋅Hochster, Howard S⋅Hochster, Howard S. and Hochster, Howard S.Journal of Clinical Oncology, vol. 38, (no. 4_suppl), pp. TPS461, 2020-02-01.
| Journal Article
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium studyMamdani, Hirva⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Kasi, Pashtoon Murtaza⋅Kasi, Pashtoon Murtaza⋅Kasi, Pashtoon Murtaza⋅Kasi, Pashtoon Murtaza⋅Kasi, Pashtoon Murtaza⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Perkins, Susan⋅Perkins, Susan⋅Perkins, Susan⋅Perkins, Susan⋅Perkins, Susan⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim and Jalal, Shadia IbrahimJournal of Clinical Oncology, vol. 38, (no. 4_suppl), pp. 404, 2020-02-01.
| Journal Article
The Case for Maintenance Pemetrexed Plus BevacizumabHanna, Nasser⋅Hanna, Nasser⋅Jalal, Shadia and Jalal, ShadiaJournal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, (no. 7), pp. 771, 2020-Mar-01.
| Journal Article
2019
Acceptance and Commitment Therapy for Symptom Interference in Advanced Lung Cancer and Caregiver Distress: A Pilot Randomized TrialMosher, Catherine E⋅Mosher, Catherine E⋅Mosher, Catherine E⋅Mosher, Catherine E⋅Mosher, Catherine E⋅Mosher, Catherine E⋅Mosher, Catherine E⋅Mosher, Catherine E⋅Secinti, Ekin⋅Secinti, Ekin⋅Secinti, Ekin⋅Secinti, Ekin⋅Secinti, Ekin⋅Secinti, Ekin⋅Secinti, Ekin⋅Secinti, Ekin⋅Hirsh, Adam T⋅Hirsh, Adam T⋅Hirsh, Adam T⋅Hirsh, Adam T⋅Hirsh, Adam T⋅Hirsh, Adam T⋅Hirsh, Adam T⋅Hirsh, Adam T⋅Hanna, Nasser⋅Hanna, Nasser⋅Hanna, Nasser⋅Hanna, Nasser⋅Hanna, Nasser⋅Hanna, Nasser⋅Hanna, Nasser⋅Hanna, Nasser⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Durm, Gregory⋅Durm, Gregory⋅Durm, Gregory⋅Durm, Gregory⋅Durm, Gregory⋅Durm, Gregory⋅Durm, Gregory⋅Durm, Gregory⋅Champion, Victoria L⋅Champion, Victoria L⋅Champion, Victoria L⋅Champion, Victoria L⋅Champion, Victoria L⋅Champion, Victoria L⋅Champion, Victoria L⋅Champion, Victoria L⋅Johns, Shelley A⋅Johns, Shelley A⋅Johns, Shelley A⋅Johns, Shelley A⋅Johns, Shelley A⋅Johns, Shelley A⋅Johns, Shelley A and Johns, Shelley AJournal of Pain and Symptom Management, vol. 58, (no. 4), Oct 2019.
| Journal Article
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumorsSharman, Jeffrey P⋅Sharman, Jeffrey P⋅Sharman, Jeffrey P⋅Wheler, Jennifer⋅Wheler, Jennifer J⋅Wheler, Jennifer⋅Einhorn, Lawrence⋅Einhorn, Lawrence⋅Einhorn, Lawrence⋅Dowlati, Afshin⋅Dowlati, Afshin⋅Dowlati, Afshin⋅Shapiro, Geoffrey I⋅Shapiro, Geoffrey⋅Shapiro, Geoffrey⋅Hilton, John⋅Hilton, John⋅Hilton, John⋅Burke, John M⋅Burke, John M⋅Burke, John M⋅Siddiqi, Tanya⋅Siddiqi, Tanya⋅Siddiqi, Tanya⋅Whiting, Nancy⋅Whiting, Nancy⋅Whiting, Nancy⋅Jalal, Shadia I⋅Jalal, Shadia and Jalal, ShadiaInvestigational New Drugs, vol. 37, (no. 4), pp. 747, 20190815.
| Journal Article
Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumorsMamdani, Hirva and Jalal, Shadia IAnnals of Translational Medicine, vol. 7, (no. S3), pp. S155, 2019-07-00.
| Journal Article
DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC)Mamdani, Hirva⋅Chen, Jerry⋅Kim, Seongho⋅Ibrahim, Yahya⋅Asad, Mohammad Fahad Bin⋅Nieva, Jorge J⋅Feldman, Rebecca⋅Naqash, Abdul Rafeh⋅Liu, Stephen V⋅Ma, Patrick C⋅Portnoy, David Craig⋅Borghaei, Hossein⋅Abdel Karim, Nagla Fawzy⋅Boumber, Yanis⋅Vanderwalde, Ari M⋅Spira, Alexander I and Jalal, Shadia IbrahimJournal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 9100, 2019-05-20.
| Journal Article
Doppler fluctuation spectroscopy of intracellular dynamics in living tissueLi, Zhe⋅Li, Zhe⋅Li, Zhe⋅Sun, Hao⋅Sun, Hao⋅Sun, Hao⋅Turek, John⋅Turek, John⋅Turek, John⋅Jalal, Shadia⋅Jalal, Shadia⋅Jalal, Shadia⋅Childress, Michael⋅Childress, Michael⋅Childress, Michael⋅Nolte, David D⋅Nolte, David D and Nolte, David DJournal of the Optical Society of America. A, Optics, image science, and vision, vol. 36, (no. 4), pp. 677, 2019-Apr-01.
| Journal Article
Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059Wainberg, Zev A⋅Wainberg, Zev A⋅Yoon, Harry H⋅Yoon, Harry H⋅Catenacci, Daniel V.T⋅Catenacci, Daniel V.T⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Muro, Kei⋅Muro, Kei⋅Garrido, Marcelo⋅Garrido, Marcelo⋅Golan, Talia⋅Golan, Talia⋅Doi, Toshihiko⋅Doi, Toshihiko⋅Geva, Ravit⋅Geva, Ravit⋅Ku, Geoffrey Yuyat⋅Ku, Geoffrey Yuyat⋅Bleeker, Jonathan Scott⋅Bleeker, Jonathan Scott⋅Bang, Yung-Jue⋅Bang, Yung-Jue⋅Hara, Hiroki⋅Hara, Hiroki⋅Chung, Hyun Cheol⋅Chung, Hyun Cheol⋅Wang, Jiang Dian⋅Wang, Jiang Dian⋅Hazzard, Andrea⋅Hazzard, Andrea⋅Shah, Sukrut⋅Shah, Sukrut⋅Fuchs, Charles S and Fuchs, Charles SJournal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 4009, 2019-05-20.
| Journal Article
Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidenceNguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh and Ceppa, DuyKhanhJournal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 6578, 2019-05-20.
| Journal Article
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYoon-Koo, Kang⋅Catenacci, Daniel V⋅Muro, Kei⋅Fuchs, Charles S⋅Geva, Ravit⋅Hara, Hiroki⋅Golan, Talia⋅Garrido, Marcelo⋅Jalal, Shadia I⋅Borg, Christophe⋅Doi, Toshihiko⋅Yoon, Harry H⋅Savage, Mary J⋅Wang, Jiangdian⋅Dalal, Rita P⋅Shah, Sukrut⋅Wainberg, Zev A and Chung, Hyun CGastric Cancer, vol. 22, (no. 4), pp. 828-837, 2019.
| Journal Article
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and HGubens, Matthew A⋅Sequist, Lecia V⋅Stevenson, James P⋅Powell, Steven F⋅Villaruz, Liza C⋅Gadgeel, Shirish M⋅Langer, Corey J⋅Patnaik, Amita⋅Borghaei, Hossein⋅Jalal, Shadia I⋅Fiore, Joseph⋅Saraf, Sanatan⋅Raftopoulos, Harry and Gandhi, LeenaLung Cancer, vol. 130, pp. 66, April 2019.
| Journal Article
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from Big Ten Cancer Research Consortium studyMamdani, Hirva⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Perkins, Susan M⋅Perkins, Susan M⋅Perkins, Susan M⋅Perkins, Susan M⋅Perkins, Susan M⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim and Jalal, Shadia IbrahimJournal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 4058, 2019-05-20.
| Journal Article
Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium studyMamdani, Hirva⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Schneider, Bryan J⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Abushahin, Laith I⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Birdas, Thomas J⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Kesler, Kenneth⋅Lee, Ahran⋅Lee, Ahran⋅Lee, Ahran⋅Lee, Ahran⋅Lee, Ahran⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Perkins, Susan⋅Perkins, Susan⋅Perkins, Susan⋅Perkins, Susan⋅Perkins, Susan⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim and Jalal, Shadia IbrahimJournal of Clinical Oncology, vol. 37, (no. 4_suppl), pp. 5, 2019-02-01.
| Journal Article
2018
24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.Borghaei, Hossein⋅Langer, Corey J⋅Gadgeel, Shirish⋅Papadimitrakopoulou, Vassiliki A⋅Patnaik, Amita⋅Powell, Steven F⋅Gentzler, Ryan D⋅Martins, Renato G⋅Stevenson, James P⋅Jalal, Shadia I⋅Panwalkar, Amit⋅Chih-Hsin Yang, James⋅Gubens, Matthew⋅Sequist, Lecia V⋅Awad, Mark M⋅Fiore, Joseph⋅Saraf, Sanatan⋅Keller, Steven and Gandhi, LeenaJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, August 20, 2018.
| Journal Article
24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLCGentzler, Ryan D⋅Gentzler, Ryan D⋅Langer, Corey J⋅Langer, Corey J⋅Borghaei, Hossein⋅Borghaei, Hossein⋅Gadgeel, Shirish M⋅Gadgeel, Shirish M⋅Papadimitrakopoulou, Vassiliki⋅Papadimitrakopoulou, Vassiliki⋅Patnaik, Amita⋅Patnaik, Amita⋅Powell, Steven Francis⋅Powell, Steven Francis⋅Martins, Renato G⋅Martins, Renato G⋅Stevenson, James⋅Stevenson, James⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Panwalkar, Amit W⋅Panwalkar, Amit W⋅Yang, James Chih-Hsin⋅Yang, James Chih-Hsin⋅Gubens, Matthew A⋅Gubens, Matthew A⋅Sequist, Lecia V⋅Sequist, Lecia V⋅Awad, Mark M⋅Awad, Mark M⋅Fiore, Joseph⋅Fiore, Joseph⋅Saraf, Sanatan⋅Saraf, Sanatan⋅Keller, Steven M⋅Keller, Steven M⋅Gandhi, Leena and Gandhi, LeenaJournal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. 9026, 2018-05-20.
| Journal Article
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase 1b StudyKim, Edward S⋅Kelly, Karen⋅Paz-Ares, Luis⋅Garrido, Pilar⋅Jalal, Shadia⋅Mahadevan, Daruka⋅Guttierrez, Martin A⋅Provencio, Mariano⋅Schaefer, Eric⋅Shaheen, Montaser⋅Johnston, Erica L⋅Turner, P Kellie⋅Kambhampati, Siva Rama P⋅Beckmann, Richard⋅Hossain, Anwar⋅John, William J and Goldman, Jonathan WClinical cancer research : an official journal of the American Association for Cancer Research, 2018-Aug-06.
| Journal Article
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib StudyKim, Edward⋅Kelly, Karen⋅Paz-Ares, Luis⋅Garrido, Pilar⋅Jalal, Shadia⋅Mahadevan, Daruka⋅Gutierrez, Martin⋅Provencio, Mariano⋅Schaefer, Eric⋅Shaheen, Monte⋅Johnston, Erica⋅Turner, P⋅Kambhampati, Siva⋅Beckmann, Richard⋅Hossain, Anwar⋅John, William and Goldman, Jonathan2018-11-01.
| Journal Article
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib StudyKim, Edward S⋅Kim, E.S.⋅Kelly, K.⋅Kelly, Karen⋅Paz-Ares, Luis G⋅Paz-Ares, L.G.⋅Garrido, Pilar⋅Garrido, P.⋅Jalal, S.⋅Jalal, Shadia⋅Mahadevan, D.⋅Mahadevan, Daruka⋅Gutierrez, Martin⋅Gutierrez, M.⋅Provencio, Mariano⋅Provencio, M.⋅Schaefer, E.⋅Schaefer, Eric⋅Shaheen, Monte⋅Shaheen, M.⋅Johnston, Erica L⋅Johnston, E.L.⋅Turner, P. Kellie⋅Kellie Turner, P.⋅Kambhampati, Siva Rama Prasad⋅Kambhampati, S.R.P.⋅Beckmann, R.⋅Beckmann, Richard⋅Hossain, A.⋅Hossain, Anwar⋅John, William J⋅John, W.J.⋅Goldman, J.W. and Goldman, Jonathan WClinical Cancer Research, vol. 24, (no. 22), pp. 5551, 2018-11-15.
| Journal Article
